Record Details

Sorbents for Extracorporeal Removal of Toxic Substances and Molecules with Adverse Biological Activity (Review)

General Reanimatology

View Archive Info
 
 
Field Value
 
Title Sorbents for Extracorporeal Removal of Toxic Substances and Molecules with Adverse Biological Activity (Review)
Сорбенты для экстракорпорального удаления токсических веществ и молекул с нежелательной биологической активностью (обзор)
 
Creator A. Morozov S.; JSC “Advanced Medical Technologies”
I. Bessonov V.; JSC “Advanced Medical Technologies”
A. Nuzhdina V.; Bauman Moscow State Technical University
V. Pisarev M.; V. A. Negovsky Research Institute of General Reanimatology
А. Морозов С.; АО Перспективные медицинские технологии
И. Бессонов В.; АО Перспективные медицинские технологии
А. Нуждина В.; Московский государственный технический университет им. Н. Э. Баумана
В. Писарев М.; НИИ общей реаниматологии им. В. А. Неговского
 
Subject sorbent; plasmasorbent; hemoperfusion; absorbing polymer material; sepsis; extracorporeal therapy
гемосорбент; плазмосорбент; сорбирующий полимерный материал; сепсис; экстракор поральная терапия
 
Description The review devoted to sorbents and sorbentbased medical devices used in clinical practice for extracorporeal detoxification using a hemoperfusion technique. Clinical data have confirmed the effectiveness of this approach for removal of bacterial endotoxins, lowdensity lipoproteins, and bilirubin. Other studies demonstrated successful application of sorbents to treat autoimmune diseases. Special attention is paid to hemoperfusion in as a possible treatment for severe sepsis and septic shock. The review justifies importance of development and application of novel multimodal sorbents, which combine both properties of selective and nonselective sorbents. The review discusses clinical efficacy of hemoperfusion and key molecular interactions between the sorbent and circulating molecules pathogenetically relevant to developing critical illness and severe diseases. The reference list: 137.
В обзоре рассмотрены сорбенты и медицинские изделия на их основе, применяемые в клинической практике для экстракорпоральной детоксикации с помощью процедуры гемосорбции. Представлены данные исследователей, свидетельствующие об эффективности такого подхода с целью удаления бактериальных эндотоксинов, липопротеинов низкой плотности, билирубина, а также при лечении аутоиммунных заболеваний. Основное внимание уделено применению гемосорбции при лечении тяжелого сепсиса и септического шока. Обосновывается необходимость разработки и применения новых «мультимодальных» сорбентов, сочетающих свойства как «селективных», так и «неселективных» сорбентов. В обзоре приведены сведения о клинической эффективности гемосорбции и молекулярном взаимодействии сорбента с циркулирующими молекулами, патогенетически значимыми для развития критических состояний и тяжелых заболеваний. Библиография — 137 ссылок.
 
Publisher FSBI "SRIGR" RAMS
 
Contributor —
—
 
Date 2017-01-25
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Рецензированная статья
 
Format application/pdf
 
Identifier http://www.reanimatology.com/rmt/article/view/1564
10.15360/1813-9779-2016-6-82-107
 
Source General Reanimatology; Том 12, № 6 (2016); 82-107
Общая реаниматология; Том 12, № 6 (2016); 82-107
2411-7110
1813-9779
10.15360/1813-9779-2016-6
 
Language rus
 
Relation http://www.reanimatology.com/rmt/article/view/1564/1074
Toshiaki I. Hemoadsorption in critical care. Ther. Apher. 2002; 6 (3): 189–192. http://dx.doi.org/10.1046/j.15260968.2002.00430.x.PMID: 12109941
Winchester J.F., Ronco C., Brady J.A., Clemmer J., Muller T.E., Davankov V., Tsyurupa M., Pavlova L., Pavlov M., Levin N.W. History of sorbents in uremia. Contrib. Nephrol. 2001; 133: 131–139. http://dx.doi.org/10.1159/000060120. PMID: 11477746
Ash S.R. Extracorporeal blood detoxification by sorbents in treatment of hepatic encephalopathy. Adv. Ren. Replace Ther. 2002; 9 (1): 3–18. http://dx.doi.org/10.1053/jarr.2002.30474. PMID: 11927902
Winchester J.F., Salsberg J.A. Sorbents in the treatment of renal failure. Minerva Urol. Nefrol. 2004; 56 (3): 215–221. PMID: 15467500
Shoji H., Tani T., Hanasawa K., Kodama M. Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application. Ther. Apher. 1998; 2 (1): 3–12. http://dx.doi.org/10.1111/j.17449987.1998.tb00066.x.PMID: 10227782
Ronco C. Endotoxin removal: history of a mission. Blood Purif. 2014; 37 (Suppl 1): 5–8. http://dx.doi.org/10.1159/000356831. PMID: 24457488
Ash S.R. Hemodiabsorption in treatment of acute hepatic failure and chronic cirrhosis with ascites. Artif. Organs. 1994; 18 (5): 355–362. http://dx.doi.org/10.1111/j.15251594.1994.tb02216.x. PMID: 8037609
Mitzner S.R., Stange J., Klammt S., Peszynski P., Schmidt R., Noldge Schomburg G. Extracorporeal detoxification using molecular adsorbent recirculating system for critically ill patients with liver failure. J. Am. Soc. Nephrol. 2001; 12 (Suppl 17): S75–S82. PMID: 11251037
Winchester J.F., Ronco C., Brady J.A., Cowgill L.D., Salsberg J., Yousha E., Choquette M., Albright R., Clemmer J., Davankov V., Tsyurupa M., Pavlova L., Pavlov M., Cohen G., HörlW., Gotch F., Levin N.W. The next step from highflux dialysis: application of sorbent technology. Blood Purif. 2002; 20 (1): 81–86. http://dx.doi.org/10.1159/000046989. PMID: 11803163
Geiger H., Klepper J., Lux P., Heidland A. Biochemical assessment and clinical evaluation of a bilirubin adsorbent column (BR350) in critically ill patients with intractable jaundice. Int. J. Artif. Organs. 1992; 15 (1): 35–39. PMID: 1551726
Tabei K., Akai Y., Takeda S., Homma S., Kusano E., Asano Y. Application of plasma perfusion in hepaticfailure. Biomater. Artif. Cells Immobilization Biotechnol. 1991; 19 (1): 193–201. http://dx.doi.org/10.3109/10731199109117826. PMID: 1751670
Mikhalovsky S.V. Microparticles for hemoperfusion and extracorporeal therapy. In: Arshady R. (ed.). Microspheres, microcapsules and liposomes. The MML Series, vol. 2: medical & biotechnology applications. London: Citus Books; 1999: 133–169.
Gordon A., Lewin A.J., Maxwell M.H., Roberts M. Current status of dialysate regeneration for the treatment of chronic uremia. In: Chang T.M.S. (ed.). Artificial kidney, artificial liver, and artificial cells. N.Y.: Plenum Press; 1978: 23–32. http://dx.doi.org/10.1007/9781468424782_4
Sangster B., van Heijst A.N.P., Sixma J.J. The influence of hemoperfusion on hemostasis and cellular constituents of the blood in the treatment of intoxications — a comparative study of 3 types of columns (Haemocol, Amberlite XAD4, Gambro Adsorba 300oC). Arch. Toxicol. 1981; 47 (4): 269–278. http://dx.doi.org/10.1007/bf00332393. PMID: 7271453
Clark W.T., III. Biocompatible hemoperfusion system. United States patent US4048064 (USA). 1977 Sept 13.
Cerulli N., La Greca G., Laville M., Palla R., Ramello A., Ghezzi P.M., Fouque D., Pizzarelli F., Schena F.P., Tetta C., Buades J., Camussi G., David S., Hoerl W., Triolo G., Maggiore U., Chiarulli G., Losurdo N., Petrarulo F., Sacchetti A., Pallotta G., Dagostino F., Del Mastro G., Sasdelli M., Mura C., Bongiorno P., Grill A., Varvara M., Carabellese S., Laraia E., Rizzi R., Mancini A., Losappio R., Maiorca R., Movilli E., Scolari F., Fiorini F., Imperatore P., Ranieri F., Bozzi M., Cuzzola R., De Min A., Specchio A., Bonomini M., Cuonzo M.T., Di Bari M., Dogliani M., Fidelio T., Ghezzi P.M., Meinero S., Canepari G., Surian M., Bonforte G., Rivera R., Sangalli L., Broccoli R., Maggiore Q., Pizzarelli F., Cavatorta F., Zollo A., Mastrangelo F., De Blasi V., Alfonso L., Usberti M., Rondina M., Laville M., Fouque D., Combarnous F., Basile C., Giordano R., Palla R., Betti G., Lopez T., Casino F., Ponticelli C., Valenti G., Ambroso G., Como G., di Belgioioso G.B., Bertoli S., Buzzi L., Albertazzi A., Lucchi L., Virgilio M., Giancaspro V., Pastore G., Conversano A., Testa A., Malcangi U., Reina E., Rusconi L., Meterangelis A., Amato M., Campolo G., Giachino G., Chiappero F., Carozzi S., Schelotto C., Sanna A., Stallone C., Aucella F., Ramello A., Marangella M., Vitale C., Quarello F., Formica M., Gastaldi L., Frattini G.M., Ervo R., Mij M., Baroni A., Borzumati M., Maschio G., Tessitore N., Loschiavo C., La Greca G., Brendolan A., Sessa A., Conte F., Ancarani E., Costantini S., Galliani M., Lorenz M., Robba C. The effect of hemodiafiltration with online endogenous reinfusion (online HFR) on anemia: design of a European, open, randomised, multicentre trial. J. Nephrol. 2000; 13 (1): 34–42. PMID: 10720212
Falkenhagen D., Strobl W., Hartmann T., Schrefl A., Linsberger I., Kellner K.H., Aussenegg Z., Leitner A. Patient safety technology extracorporeal for microadsorbent systems in blood purification. Artif. Organs. 2002; 26 (2): 84–90. http://dx.doi.org/10.1046/j.15251594.2002.06884.x. PMID: 11879234
Yu Y.T., Chen C.Z. Advances of adsorbents for hemoperfusion in China. Biomater. Artif. Cells Artif. Organs. 1990; 18 (4): 499–505. http://dx.doi.org/10.3109/10731199009119624. PMID: 2285812
Bansal R.C., Donnet J.B., Stoeckli F. (eds.). Active carbon. N.Y.: Marcel Dekker; 1988: 482.
Cipoletti J.J. Resin technology in medicine. In: Cipoletti J.J., Kunin R., Meyer F. Sorbents and their clinical applications. N.Y.: Academic Press; 1980: 221–248.
Афанасьева O.K., Алтынова Е.В., Болдырев А.Г., Соколов А.А., Адамова И.Ю., Покровский С.H. Сравнительный анализ эффективности и специфичности разных сорбентов для афереза липопротеидов низкой плотности. Бюл. эксперим. биологии и медицины. 2006; 142 (11): 532–536. http://dx.doi.org/10.1007/s1051700604254. PMID: 17415469
Yokoyama S., Hayashi R., Satani M., Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholes terolemia. Arteriosclerosis. 1985; 5 (6): 613–622. http://dx.doi.org/10.1161/01.atv.5.6.613. PMID: 3865648
Koll R.A. LDLTherasorb immunoadsorption for the treatment of severe hypercholesterolemia refractory to conventional therapy. Ther. Apher. 1998; 2 (2): 142–146. http://dx.doi.org/10.1111/j.17449987.1998.tb00092.x. PMID: 10225716
Bosch T. Recent advances in therapeutic apheresis. J. Artif. Organs. 2003; 6 (l): 1–8. http://dx.doi.org/10.1007/s100470300000. PMID: 14598117
Thompson G.R. LDL apheresis. Atherosclerosis. 2003; 167 (1): 1–13. http://dx.doi.org/10.1016/s00219150(02)002514. PMID: 12618263
NewsomDavis J. Autoimmunity in neuromuscular disease. Ann. N. Y. Acad. Sci. 1988; 540: 25–38. http://dx.doi.org/10.1111/j.17496632.1988.tb27048.x. PMID: 2849891
Bradl M., Lassmann H. Neurologic autoimmunity: mechanisms revealed by animal models. Handb. Clin. Neurol. 2016; 133: 121–143. http://dx.doi.org/10.1016/B9780444634320.000086. PMID: 27112675
Gilhus N.E., Skeie G.O., Romi F., Lazaridis K., Zisimopoulou P., Tzartos S. Myasthenia gravis — autoantibody characteristics and their implica tions for therapy. Nat. Rev. Neurol. 2016; 12 (5): 259–268. http://dx.doi.org/10.1038/nrneurol.2016.44. PMID: 27103470
Von Thun Und HohensteinBlaul N., Bell K., Pfeiffer N., Grus F.H. Autoimmune aspects in glaucoma. Eur. J. Pharmacol. 2016; 787: 105–118. http://dx.doi.org/10.1016/j.ejphar.2016.04.031. PMID: 27090926
Lally L., Sammaritano L.R. Vasculitis in antiphospholipid syndrome. Rheum. Dis. Clin. North Am. 2015; 41 (1): 109–123. http://dx.doi.org/10.1016/j.rdc.2014.09.009. PMID: 25399943
Conigliaro P., Chimenti M.S., Triggianese P., Sunzini F., Novelli L., Perricone C., Perricone R. Autoantibodies in inflammatory arthritis. Autoimmun. Rev. 2016; 15 (7): 673–683. http://dx.doi.org/10.1016/j.autrev.2016.03.003. PMID: 26970491
Sueoka A. Present status of apheresis technologies, part 3: adsorbent. Ther. Apher. 1997; 1 (3): 271–283. http://dx.doi.org/10.1111/j.17449987.1997.tb00150.x. PMID: 10225751
Hashimoto H., Tsuda H., Kanai Y., Kobayashi S., Hirose S., Shinoura H., Yokohari R., Kinoshita M., Aotsuka S., Yamada H., Takahashi K., Yoshiyama S., Miyamoto T. Selective removal of antiDNA and anticar diolipin antibodies by adsorbent plasmapheresis using dextran sulfate columns in patients with systemic lupus erythematosus. J. Rheumatol. 1991; 18 (4): 545–551. PMID: 2066947
Wiesenhuter C., Irish B., Bertram J. Treatment of patients with refractory rheumatoid arthritis with extracorporeal proteinA immunoadsorption column: a pilot trial. J. Rheumatol. 1994; 21 (5): 804–812. PMID: 8064718
Falson D.T., LaValley M.P., Baldassare A.R., Block J.A., Caldwell J.R., Cannon G.W., Deal C., Evance S., Fleischmann R., Gendreau R.M., Harris E.R., Matteson E.L., Roth S.H., Schumacher H.R., Weisman M.H., Furst D.E. The Prosorba column for treatment of refractory rheumatoid arthritis: A randomized, doubleblind, shamcontrolled trial. Arthritis. Rheum. 1999; 42 (10): 2153–2159. http://dx.doi.org/10.1002/15290131(199910)42:10<2153::aidanr16>3.0.co;2w. PMID: 10524687
Braun N., Risler T. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther. Apher. 1999; 3 (3): 240– 245. http://dx.doi.org/10.1046/j.15260968.1999.00155.x. PMID: 10427622
Oka K., Nakaji S., Tanihara M., Takakura K., Takamori M. Development of specific immunoadsorbent containing immobilized synthetic peptide of acetylcholine receptor for treatment of myasthenia gravis. Jpn. J. Artif. Organs. 1993; 22: 194–197.
Nakaji S., Oka K., Tanihara M., Takakura K., Takamori M. Development of a specific immunoadsorbent containing immobilized synthetic peptide of acetylcholine receptor for treatment of myasthenia gravis. 1993. Ther. Apher. 2000; 4 (2): 124–126. http://dx.doi.org/10.1046/j.15260968.2000.004002124.x. PMID: 10805430
Koll R.A. IgTherasorb immunoadsorption for selective removal of human immunoglobulin diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins. Ther. Apher. 1998; 2 (2): 147–152. http://dx.doi.org/10.1111/j.17449987.1998.tb00093.x. PMID: 10225717
Kutsuki H., Takata S., Yamamoto K., Tani N. Therapeutic selective adsorption of antiDNA antibody using dextran sulfate cellulose column (Selesorb) for the treatment of systemic lupus erythematosus. Ther. Apher. 1998; 2: 18–24. http://dx.doi.org/10.1111/j.17449987.1998.tb00068.x. PMID: 10227784
Pokrovsky S., Kuznetsova Yu.V., Afanasieva O.I., Zvezdkin P.V., Adamova I. Yu., Konovalov G.A. Clinical experience of immunoadsorption with ‘Ig Adsopak’ columns. Ther. Apher. Dial. 2005; 9 (5): A38. http://dx.doi.org/10.1111/j.17449987.2005.00324_4.x
Zahir F., Rabbani G., Khan R.H., Rizvi S.J., Jamal M.S., Abuzenadah A.M. The pharmacological features of bilirubin: the question of the century. Cell Mol. Biol. Lett. 2015; 20 (3): 418–447. http://dx.doi.org/10.1515/cmble20150012. PMID: 26208389
Qaisiya M., Brischetto C., Jašprová J., Vitek L., Tiribelli C., Bellarosa C. Bilirubininduced ER stress contributes to the inflammatory response and apoptosis in neuronal cells. Arch. Toxicol. 2016; [Epub ahead of print]. http://dx.doi.org/10.1007/s0020401618353. PMID: 27578021
Ahlfors C. Plasma bilirubin binding and bilirubin neurotoxicity. Dev. Med. Child Neurol. 2016; [Epub ahead of print]. http://dx.doi.org/10.1111/dmcn.13303. PMID: 27786370
Riordan S.M., Bittel D.C., Le Pichon J.B., Gazzin S., Tiribelli C., Watchko J.F., Wennberg R.P., Shapiro S.M. A hypothesis for using pathway genetic load analysis for understanding complex outcomes in bilirubin encephalopathy. Front Neurosci. 2016; 10: 376. http://dx.doi.org/10.3389/fnins.2016.00376. PMID: 27587993
Watchko J.F. Bilirubininduced neurotoxicity in the preterm neonate. Clin. Perinatol. 2016; 43 (2): 297–311. http://dx.doi.org/10.1016/j.clp.2016.01.007. PMID: 27235209
Bhutani V.K., Wong R.J., Stevenson D.K. Hyperbilirubinemia in preterm neonates. Clin. Perinatol. 2016; 43 (2): 215–232. http://dx.doi.org/10.1016/j.clp.2016.01.001. PMID: 27235203
Amin S.B., Wang H., Laroia N., Orlando M. Unbound bilirubin and auditory neuropathy spectrum disorder in late preterm and term infants with severe jaundice. J. Pediatr. 2016; 173: 84–89. http://dx.doi.org/10.1016/j.jpeds.2016.02.024. PMID: 26952116
Wusthoff C.J., Loe I.M. Impact of bilirubininduced neurologic dysfunction on neurodevelopmental outcomes. Semin. Fetal. Neonatal. Med. 2015; 20 (1): 52–57. http://dx.doi.org/10.1016/j.siny.2014.12.003. PMID: 25585889
Olusanya B.O. Societal impact of bilirubininduced hearing impairment in resourcelimited nations. Semin. Fetal. Neonatal. Med. 2015; 20 (1): 58–63. http://dx.doi.org/10.1016/j.siny.2014.12.009. PMID:25573775
Gazzin S., Vitek L., Watchko J., Shapiro S.M., Tiribelli C. A novel perspective on the biology of bilirubin in health and disease. Trends Mol. Med. 2016; 22 (9): 758–768. http://dx.doi.org/10.1016/j.molmed.2016.07.004. PMID: 27515064
Tan H.K. Molecular Adsorbent Recirculating System (MARS). Ann. Acad. Med. Singapore. 2004; 33 (3): 329–335. PMID: 15175774
Collins K.L., Roberts E.A., Adeli K., Bohn D., Harvey E.A. Single pass albumin dialysis (SPAD) in fulminant Wilsonian liver failure: a case report. Pediatr. Nephrol. 2008; 23 (6): 1013–1016. http://dx.doi.org/10.1007/s004670080761x. PMID: 18299897
Mitzner S., Klammt S., Stange J., Schmidt R. Albumin regeneration in liver supportcomparison of different methods. Ther. Apher. Dial. 2006; 10 (2): 108–117. http://dx.doi.org/10.1111/j.17449987.2006.00351.x.PMID: 16684211
Takenaka Y. Bilirubin adsorbent column for plasma perfusion. Ther. Apher. 1998; 2 (2): 129–133. http://dx.doi.org/10.1111/j.17449987.1998.tb00090.x. PMID: 10225714
Nakaji S., Hayashi N. Bilirubin adsorption column Medisorba BL300. Ther. Apher. Dial. 2003; 7 (1): 98–103. http://dx.doi.org/10.1046/j.15260968.2003.00007.x. PMID: 12921123
Stegmayr B.G. Plasmapheresis in severe sepsis or septic shock. Blood Purif. 1996; 14 (1): 94–101. http://dx.doi.org/10.1159/000170250. PMID: 8718572
Stegmayr B.G. Is there a future for adsorption techniques in sepsis? Blood Purif. 2000; 18 (2): 149–155. http://dx.doi.org/10.1159/000014440. PMID: 10838475
Rimmelé T., Kellum J.A. Clinical review: blood purification for sepsis. Crit. Care. 2011; 15 (1): 205. http://dx.doi.org/10.1186/cc9411. PMID: 21371356
Воинов В.А. Эфферентная терапия критических состояний в реаниматологии. СПб.: СанктПетербургский ГМУ им. И.П.Павлова; 2013: 110.
Davies B., Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect. Dis. 2011; 11 (1): 65–71. http://dx.doi.org/10.1016/s14733099(10)702206. PMID: 21183148
Бажина Е.С., Никулин А.В., Хорошилов С.Е. Экстракорпоральные методы лечения абдоминального сепсиса. Общая реаниматология. 2015; 11 (5): 4566. http://dx.doi.org/10.15360/18139779201554566
Ушакова Н.Д., Шевченко А.Н., Четвериков М.В., Златник Е.Ю., Зыкова Т.А. Результаты применения селективной адсорбции эндотоксина при сепсисе у онкологических больных. Общая реаниматология. 2014; 10 (6): 32–38. http://dx.doi.org/10.15360/18139779201463238
Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther. Apher. Dial. 2003; 7 (1): 108–114. http://dx.doi.org/10.1046/j.15260968.2003.00005.x.PMID:12921125
Nakamura T., Kawagoe Y., Suzuki T., Shoji H., Ueda Y., Koide H. Polymyxin B–immobilized fiber hemoperfusion with the PMX05R column in elderly patients suffering from septic shock. Am. J. Med. Sci. 2007; 334 (4): 244–247. http://dx.doi.org/10.1097/MAJ.0b013e3180a5e8d8. PMID: 18030179
Toray Medical Co., Ltd. for endotoxin removal in patients with severe sepsis and septic shock. http://www.toraymedical.com/en/medical/kyusei/pdf/PMX20R.pdf
Kojika M., Sato N., Yaegashi Y., Suzuki Y., Suzuki K., Nakae H., Endo S. Endotoxin adsorption therapy for septic shock using polymyxin B immobilized fibers (PMX): evaluation by highsensitivity endotoxin assay and measurement of the cytokine production capacity. Ther. Apher. Dial. 2006; 10 (1): 12–18. http://dx.doi.org/10.1111/j.17449987.2006.00340.x. PMID: 16556131
Shoji H., Minaga M., Sakai Y., Kunitomo T., Takeyama T., Tani T., Kodama M. Design and development of endotoxin detoxifying column PMX and its clinical application. Jpn. J. Artif. Organs. 1993; 22 (1): 204–211.
Sakai Y., Shoji H., Kobayashi T., Terada R., Sugaya H., Murakami R., Moriyama K., Minaga M., Kunitomo N., Takeyama T. New extracorpo real blood purification devices for critical care medicine under devel opment. Ther. Plasmapheresis. 1993; 12: 837–842.
Shimizu T., Obata T., Sonoda H., Akabori H., Tabata T., Eguchi Y., Endo Y., Tani T. The ability of endotoxin adsorption during a longer duration of direct hemoperfusion with a polymyxin Bimmobilized fiber columnin patients with septic shock. Transfus. Apher. Sci. 2013; 49 (3): 499–503. http://dx.doi.org/10.1016/j.transci.2013.04.042. PMID: 23683501
Jaber B.L., Barrett T.W., Cendoroglo Neto M., Sundaram S., King A.J., Pereira B.J. Endotoxin removal by polymyxinB immobilized polystyrenederivative fibers during in vitro hemoperfusion of 10% human plasma. ASAIO J. 1998; 44 (1): 54–61. http://dx.doi.org/10.1097/0000248019980100000012. PMID: 9466502
Tani T., Hanasawa K., Kodama M., Imaizumi H., Yonekawa M., Saito M., Ikeda T., Yagi Y., Takayama K., Amano I., Shimaoka H., Ohta M., Okahisa T., Koga N., Fujita N., Yamasa H. Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor1 activities in septic patients. World J. Surg. 2001; 25 (5): 660–668. http://dx.doi.org/10.1007/s002680020028. PMID: 11396436
Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Maeda S., Yamagishi S. Suppression of highmobility group box1 and receptor for advanced glycation endproduct axis by polymyxin B–immobilized fiber hemop erfusion in septic shock patients. J. Crit. Care. 2011; 26 (6): 546– 549. http://dx.doi.org/10.1016/j.jcrc.2010.11.010. PMID: 21273029
Oishi K., MimuraKimura Y., Miyasho T., Aoe K., Ogata Y., Katayama H., Murata Y., Ueoka H., Matsumoto T., Mimura Y. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine. 2013; 61 (1): 84–89. http://dx.doi.org/10.1016/j.cyto.2012.08.032. PMID: 23021430
Shimizu T., Hanasawa K., Sato K., Umeki M., Koga N., Naganuma T., Sato S., Shimonishi T., Ikeda T., Matsuno N., Ono S., Saitoh H., Satoh K., Otani Y., Endo Y., Eguchi Y., Tani T.; PMX Treatment Study Group in Septic Patients with Colorectal Perforation. The clinical significance of serum procalcitonin levels following direct hemoperfusion with polymyxin Bimmobilized fiber column in septic patients with colorectal perforation. Eur. Surg. Res. 2009; 42 (2): 109–117. http://dx.doi.org/10.1159/000187169. PMID: 19122457
Hanasawa K., Tani T., Oka T., Yoshioka T., Endo Y., Horisawa M., Nakane Y., Kodama M., Teramoto K., Nishiumi S. A new treatment for endotoxemia with direct hemoperfusion by polymyxin immobilized fiber. Ther. Apher. 2000; 4 (2): 142–145. http://dx.doi.org/10.1046/j.15260968.2000.004002142.x. PMID: 10805433
Tani T., Hanasawa K., Endo Y., Yoshioka T., Kodama M., Kaneko M., Uchiyama Y., Akizawa T., Takahasi K., Sugai K. Therapeutic apheresis for septic patients with organ dysfunction: hemoperfusion using a polymyxin B immobilized column. Artif. Organs. 1998; 22 (12): 1038– 1044. http://dx.doi.org/10.1046/j.15251594.1998.06086.x. PMID: 9876096
Kodama M., Hanasawa K., Tani T. Blood purification for critical care medicine: endotoxin adsorption. Ther. Apher. 1997; 1 (3): 224–227. http://dx.doi.org/10.1111/j.17449987.1997.tb00142.x. PMID: 10225743
Cruz D.N., Perazella M.A., Bellomo R., de Cal M., Polanco N., Corradi V., Lentini P., Nalesso F., Ueno T., Ranieri V.M., Ronco C. Effectiveness of polymyxin Bimmobilized fiber column in sepsis: a systematic review. Crit. Care. 2007; 11 (2): R47. http://dx.doi.org/10.1186/cc5780.PMID: 17448226
Nakamura T., Ebihara I., Shoji H., Ushiyama C., Suzuki S., Koide H. Treatment with polymyxin Bimmobilized fiber reduces platelet activation in septic shock patients: decrease in plasma levels of soluble P selectin, platelet factor4 and betathromboglobulin. Inflamm. Res. 1999; 48 (4): 171–175. http://dx.doi.org/10.1007/s000110050442. PMID: 10344466
Nemoto H., Nakamoto H., Okada H., Sugahara S., Moriwaki K., Arai M., Kanno Y., Suzuki H. Newly developed polymyxin Bimmobilized fibers improve the survival of patients with sepsis. Blood Purif. 2001; 19 (4): 361–369. http://dx.doi.org/10.1159/000046966. PMID: 11574732
Nakamura T., Ushiyama C., Suzuki Y., Shoji H., Shimada N., Koide H. Hemoperfusion with polymyxinB immobilized fiber for urinary albumin excretion in septic patients with trauma. ASAIO J. 2002; 48 (3): 244–248. http://dx.doi.org/10.1097/0000248020020500000008. PMID: 12058997
Suzuki H., Nemoto H., Nakamoto H., Okada H., Sugahara S., Kanno Y., Moriwaki K. Continuous hemodiafiltration with polymyxin B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure. Ther. Apher. 2002; 6 (3): 234–240. http://dx.doi.org/10.1046/j.15260968.2002.00416.x. PMID: 12109950
Tsushima K., Kubo K., Koizumi T., Yamamoto H., Fujimoto K., Hora K., KanNou Y. Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory. J. Clin. Apher. 2002; 17 (2): 97–102.http://dx.doi.org/10.1002/jca.10019. PMID: 12210714
Tsugawa K., Koyanagi N., Hashizume M., Wada H., Ayukawa K., Akahoshi K., Tomikawa M., Sugimachi K. Results of endotoxin absorption after a subtotal resection of the small intestine and a right hemicolectomy for severe superior mesenteric ischemia. Hepatogastroenterology. 2002; 49 (47): 1303–1306. PMID: 12239931
Nakamura T., Ushiyama C., Suzuki Y., Inoue T., Shoji H., Shimada N., Koide H. Combination therapy with polymyxin Bimmobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillinresistant Staphylococcus aureus. J. Hosp. Infect. 2003; 53 (1): 58–63. http://dx.doi.org/10.1053/jhin.2002.1332. PMID: 12495686
Nakamura T., Ushiyama C., Suzuki Y., Osada S., Inoue T., Shoji H., Hara M., Shimada N., Koide H. Hemoperfusion with polymyxinB immobilized fiber in septic patients with methicillinresistant Staphylococcus aureusassociated glomerulonephritis. Nephron. Clin. Pract. 2003; 94 (2): 33–39. http://dx.doi.org/10.1159/000071279. PMID: 12845235
Nakamura T., Matsuda T., Suzuki Y., Shoji H., Koide H. Polymyxin B immobilized fiber in patients with sepsis. Dial. Transplant. 2003; 32: 602–607.
Nakamura T., Kawagoe Y., Matsuda T., Koide H. Effect of polymyxin B immobilized fiber on bone resorption in patients with sepsis. Intensive Care Med. 2004; 30 (9): 1838–1841. http://dx.doi.org/10.1007/s0013400423577. PMID: 15197430
Nakamura T., Kawagoe Y., Matsuda T., Ueda Y., Koide H. Effects of polymyxin Bimmobilized fiber on urinary NacetylBglu cosaminidase in patients with severe sepsis. ASAIO J. 2004; 50 (6): 563–567. http://dx.doi.org/10.1097/01.mat.0000142875.62592.3a. PMID: 15672789
Ono S., Tsujinomoto H., Matsumoto A., Ikuta S., Kinoshita M., Mochizuki H. Modulation of human leukocyte antigenDR on monocytes and CD16 on granulocytes in patients with polymyxin bimmobilized fiber. Am. J. Surg. 2004; 188 (2): 150–156. http://dx.doi.org/10.1016/j.amjsurg.2003.12.067. PMID: 15249240
Tsujimoto H., Ono S., Hiraki S., Majima T., Kawarabayashi N., Sugasawa H., Kinoshita M., Hiraide H., Mochizuki H. Hemoperfusion with polymyxin Bimmobilized fibers reduced the number of CD16+CD14+ monocytes in patients with septic shock. J. Endotoxin. Res. 2004; 10 (4): 229–237. http://dx.doi.org/10.1179/096805104225005814. PMID: 15373966
Nakamura T., Kawagoe Y., Sukuzi T., Shoji H., Ueda Y., Kobayashi N., Koide H. Changes in plasma interleukin18 by direct hemoperfusion with polymyxin Bimmobilized fiber in patients with septic shock. Blood Purif. 2005; 23 (6): 417–420. http://dx.doi.org/10.1159/000088016. PMID: 16141713
Vincent J.L., Laterre P.F., Cohen J., Burchardi H., Bruining H., Lerma F.A., Wittebole X., De Backer D., Brett S., Marzo D., Nakamura H., John S. A pilotcontrolled study of a polymyxin Bimmobilized hemoperfusion cartridge in patients with severe sepsis secondary to intraabdominal infection. Shock. 2005; 23 (5): 400–405. http://dx.doi.org/10.1097/01.shk.0000159930.87737.8a. PMID: 15834304
Nakamura T., Ebihara I., Shimada N., Suzuki S., Ushiyama C., Shoji H., Koide H. Effects of hemoperfusion with polymyxin Bimmobilized fibre on serum neopterin and soluble interleukin2 receptor concentrations in patients with septic shock. J. Infect. 1998; 37 (3): 241–247. http://dx.doi.org/10.1016/s01634453(98)919521. PMID: 9892527
Nakamura T., Ebihara I., Shimada N., Koide H. Changes in plasma erythropoietin and interleukin6 concentrations in patients with septic shock after hemoperfusion and polymyxin Bimmobilized fiber. Intensive Care Med. 1998; 24 (12): 1272–1276. http://dx.doi.org/10.1007/s001340050761. PMID: 9885879
Nakamura T., Kawagoe Y., Matsuda T., Shoji H., Ueda Y., Tamura N., Ebihara I., Koide H. Effect of polymyxin Bimmobilized fiber on blood metalloproteinase9 and tissue inhibitor of metalloproteinase1 levels in acute respiratory distress syndrome patients. Blood Purif. 2004; 22 (3): 256–260. http://dx.doi.org/10.1159/000078494. PMID: 15148453
Shimada N., Nakamura T., Takayashi Y., Tanaka A., Shoji H., Sekizuka K., Ebihara I., Koide H. Effects of polymyxin Bimmobilized fiber on serum phosphate concentrations in patients with sepsis. Nephron. 2000; 86 (3): 359–360. http://dx.doi.org/10.1159/000045800. PMID: 11096302
Tojimbara T., Sato S., Nakajima I., Fuchinoue S., Akiba T., Teraoka S. Polymyxin Bimmobilized fiber hemoperfusion after emergency surgery in patients with chronic renal failure. Ther. Apher. Dial. 2004; 8 (4): 286–292. http://dx.doi.org/10.1111/j.15260968.2004.00166.x.PMID: 15274679
Ueno T., Sugino M., Nemoto H., Shoji H., Kakita A., Watanabe M. Effect over time of endotoxin adsorption therapy in sepsis. Ther. Apher. Dial. 2005; 9 (2): 128–136. http://dx.doi.org/10.1111/j.17749987.2005.00230.x. PMID: 15828924
Uriu K., Osajima A., Hiroshige K., Watanabe H., Aibara K., Inada Y., Segawa K., Anai H., Takagi I., Ito A., Kamochi M., Kaizu K. Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin Bimmobilized fiber ameliorates systemic circulatory distur bance in patients with septic shock. Am. J. Kidney Dis. 2002; 39 (5): 937–947. http://dx.doi.org/10.1053/ajkd.2002.32767. PMID: 11979337
Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., Peterson E., Tomlanovich M.; Early GoalDirected Therapy Collaborative Group. Early goaldirected therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 2001; 345 (19): 1368–1377. http://dx.doi.org/10.1056/nejmoa010307. PMID: 11794169
Ikeda T., Ikeda K., Nagura M., Taniuchi H., Matsushita M., Kiuchi S., Kuroki Y., Suzuki K., Matsuno N. Clinical evaluation of PMXDHP for hypercytokinemia caused by septic multiple organ failure. Ther. Apher. Dial. 2004; 8 (4): 293–298. http://dx.doi.org/10.1111/j.15260968.2004.00167.x. PMID: 15274680
Casella G., Monti G., Terzi V., Pulici M., Ravizza A., Vesconi S. Nonconventional therapies in refractory septic shock: clinical experience with Polymyxin B. Minerva Anestesiol. 2006; 72 (1): 63–67.
Follmann D., Elliott P., Suh I., Cutler J. Variance imputation for overviews of clinical trials with continuous response. J. Clin. Epidemiol. 1992; 45 (7): 769–773. http://dx.doi.org/10.1016/08954356(92)90054q. PMID: 1619456
Kushi H., Miki T., Okamoto K., Nakahara J., Saito T., Tanjoh K. Early haemoperfusion with an immobilized polymyxin B fiber column elimi nates humoral mediators and improves pulmonary oxygenation. Crit. Care. 2005; 9 (6): R653–R661. http://dx.doi.org/10.1186/cc3815.PMID: 16280061
Cruz D.N., Antonelli M., Fumagalli R., Foltran F., Brienza N., Donati A., Malcangi V., Petrini F., Volta G., Bobbio Pallavicini F.M., Rottoli F., Giunta F., Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009; 301 (23): 2445–2452. http://dx.doi.org/10.1001/jama.2009.856. PMID: 19531784
Vincent J.L. Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA. 2009; 302 (18): 1967–1968. http://dx.doi.org/10.1001/jama.2009.1606. PMID: 19903915
Amaral A.C. Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA. 2009; 302 (18): 1968–1970. http://dx.doi.org/10.1001/jama.2009.1607. PMID: 19903914
Kase Y., Obata T., Okamoto Y., Iwai K., Saito K., Yokoyama K., Takinami M., Tanifuji Y. Removal of 2arachidonylglycerol by direct hemoperfusion therapy with polymyxin B immobilized fibers benefits patients with septic shock. Ther. Apher. Dial. 2008; 12 (5): 374–380. http://dx.doi.org/10.1111/j.17449987.2008.00612.x. PMID: 18937720
Cantaluppi V., Assenzio B., Pasero D., Romanazzi G.M., Pacitti A., Lanfranco G., Puntorieri V., Martin E.L., Mascia L., Monti G., Casella G., Segoloni G.P., Camussi G., Ranieri V.M. PolymyxinB hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med. 2008; 34 (9): 1638–1645. http://dx.doi.org/10.1007/s0013400811246. PMID: 18463848
Kohro S., Imaizumi H., Yamakage M., Masuda Y., Namiki A., Asai Y., Maruyama I. Anandamide absorption by direct hemoperfusion with polymixin Bimmobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis. J. Anesth. 2006; 20 (1): 11–16. http://dx.doi.org/10.1007/s0054000503665. PMID: 16421670
Matsuno N., Ikeda T., Ikeda K., Hama K., Iwamoto H., Uchiyama M., Kozaki K., Narumi Y., Kikuchi K., Degawa H., Nagao T. Changes of cytokines in direct endotoxin adsorption treatment on postoperative multiple organ failure. Ther. Apher. 2001; 5 (1): 36–39. http://dx.doi.org/10.1046/j.15260968.2001.005001036.x. PMID: 11258608
Novelli G., Ferretti G., Poli L., Pretagostini R., Ruberto F., Perrella S.M., Levi Sandri G.B., Morabito V., Berloco P.B. Clinical results of treatment of postsurgical endotoxinmediated sepsis with polymyxinB direct hemo perfusion. Transplant. Proc. 2010; 42 (4): 1021–1024. http://dx.doi.org/10.1016/j.transproceed.2010.03.056. PMID: 20534214
Mori M., Onaka T., Yonezawa A., Kitagawa T., Sasaki Y., Imada K. Direct hemoperfusion using polymyxinB immobilized fiber for severe septic patients with hematological disorders: a singlecenter analysis. J. Infect. Chemother. 2014; 20 (4): 282–284. http://dx.doi.org/10.1016/j.jiac.2013.12.008. PMID: 24485325
Mitaka C., Fujiwara N., Yamamoto M., Toyofuku T., Haraguchi G., Tomita M. Polymyxin Bimmobilized fiber column hemoperfusion removes endotoxin throughout a 24hour treatment period. J. Crit. Care. 2014; 29 (5): 728–732. http://dx.doi.org/10.1016/j.jcrc.2014.03.031.PMID: 24798345
Klein D.J., Foster D., Schorr C.A., Kazempour K., Walker P.M., Dellinger R.P. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized con trolled trial. Trials. 2014; 15: 218. http://dx.doi.org/10.1186/1745621515218. PMID: 24916483
Cutuli S.L., Artigas A., Fumagalli R., Monti G., Ranieri V.M., Ronco C., Antonelli M.; EUPHAS 2 Collaborative Group. PolymyxinB hemoper fusion in septic patients: analysis of a multicenter registry. Ann. Intensive Care. 2016; 6 (1): 77. http://dx.doi.org/10.1186/s1361301601789. PMID: 27502196
Quenot J.P., Binquet C., Kara F., Martinet O., Ganster F., Navellou J.C., Castelain V., Barraud D., Cousson J., Louis G., Perez P., Kuteifan K., Noirot A., Badie J., Mezher C., Lessire H., Pavon A. The epidemiology of septic shock in French intensive care units: the prospective multicen ter cohort EPISS study. Crit. Care. 2013; 17 (2): R65. http://dx.doi.org/10.1186/cc12598. PMID: 23561510
Phua J., Koh Y., Du B., Tang Y.Q., Divatia J.V., Tan C.C., Gomersall C.D., Faruq M.O., Shrestha B.R., Gia Binh N., Arabi Y.M., Salahuddin N., Wahyuprajitno B., Tu M.L., Wahab A.Y., Hameed A.A., Nishimura M., Procyshyn M., Chan Y.H.; MOSAICS Study Group. Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study. BMJ. 2011; 342: d3245. http://dx.doi.org/10.1136/bmj.d3245. PMID: 21669950
Chihara S., MasudaY., Tatsumi H., Nakano K., Shimada T., Murohashi T., Yamakage M. Early induction of direct hemoperfusion with a polymyx inB immobilized column is associated with amelioration of hemody namic derangement and mortality in patients with septic shock. J. Artif. Organs. 2016; [Epub ahead of print]. http://dx.doi.org/10.1007/s1004701609229. PMID: 27469940
Kulabukhov V. Use of an endotoxin adsorber in the treatment of severe abdominal sepsis. Acta Anaesthesiol. Scand. 2008; 52 (7): 1024–1025. http://dx.doi.org/10.1111/j.13996576.2008.01677.x. PMID: 18494849
Adamik B., Zielinski S., Smiechowicz J., Kübler A. Endotoxin elimination in patients with septic shock: an observation study. Arch. Immunol. Ther. Exp. (Warsz.). 2015; 63 (6): 475– 483. http://dx.doi.org/10.1007/s0000501503488. PMID: 26093653
Mahlicli F.Y., Altinkaya S.A., Yurekli Y. Preparation and characterization of polyacrylonitrile membranes modified with polyelectrolyte deposition for separating similar sized proteins. J. Membr. Sci. 2012; 415–416 (1): 383–390. http://dx.doi.org/10.1016/j.memsci.2012.05.028
Honore P.M., Jacobs R., JoannesBoyau O., De Regt J., De Waele E., van Gorp V., Boer W., Verfaillie L., Spapen H.D. Newly designed CRRT membranes for sepsis and SIRS — a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic struc tured review. ASAIO J. 2013; 59 (2): 99–106. http://dx.doi.org/10.1097/MAT.0b013e3182816a75. PMID: 23438770
Mitzner S., Schneidewind J., Falkenhagen D., Loth F., Klinkmann H. Extracorporeal endotoxin removal by immobilized polyethylenimine. Artif. Organs. 1993; 17 (9): 775–781. http://dx.doi.org/10.1111/j.15251594.1993.tb00630.x. PMID: 8240070
Shum H.P., Chan K.C., Kwan M.C., Yan W.W. Application of endotoxin and cytokine adsorption haemofilter in septic acute kidney injury due to Gramnegative bacterial infection. Hong Kong Med. J. 2013; 19 (6): 491–497. http://dx.doi.org/10.12809/hkmj133910. PMID: 23650198
Bengsch S., Boos K.S., Nagel D., Seidel D., Inthorn D. Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock. 2005; 23 (6): 494–500. PMID:15897800
Гапанович В.Н., Кирковский В.В., Третьяк Д.С., Голубович В.П., Куцук О.Н., Старостин А.В., Мельнова Н.И., Андреев С.В. Антилипополисахаридный гемосорбент на основе сшитого полимиксина. Сообщение 1. Военная медицина. 2012; 3: 98–99.
Гапанович В.Н., Кирковский В.В., Третьяк Д.С., Голубович В.П., Андреев С.С., Мельнова Н.И., Жук И.Н. Антилипополисахаридный гемосорбент на основе сшитого полимиксина. Сообщение 2. Военная медицина. 2013; 2: 92–96.
Кирковский В.В., Гапанович В.Н., Третьяк Д.С., Старостин А.В., Добриянец А.И., Андреев С.В., Мельнова Н.И. Антилипополисахаридный гемосорбент на основе сшитого полимиксина. Сообщение 3. Военная медицина. 2013; 3: 97–100.
Скворцов Н.В., Власова О.Л., Болдырев А.Г., Ларионов И.В. Оценка эффективности сорбента Сфероцелл С80 в динамическом режиме. Научнотехнические ведомости СПбГПУ. Физикоматематические науки. 2015; 2: 91–98.
Скворцов Н.В., Самойлов В.О., Ларионов И.В., Болдырев А.Г. Эффективный сорбент для элиминации эндотоксина в биопрепаратах генноинженерного генеза и биологических жидкостях. Научно технические ведомости СПбГПУ. Физикоматематические науки. 2013; 3: 177–181.
http://toxipak.ru/column/about/
Payen D.M., Guilhot J., Launey Y., Lukaszewicz A.C., Kaaki M., Veber B., Pottecher J., JoannesBoyau O., MartinLefevre L., Jabaudon M., Mimoz O., Coudroy R., Ferrandière M., Kipnis E., Vela C., Chevallier S., Mallat J., Robert R.; ABDOMIX Group. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015; 41 (6): 975–984. http://dx.doi.org/10.1007/s001340153751z. PMID: 25862039
Sugiura M., Mitaka C., Haraguchi G., Tomita M., Inase N. Polymyxin B immobilized fiber column hemoperfusion mainly helps to constrict peripheral blood vessels in treatment for septic shock. J. Intensive Care. 2015; 3 (1): 14. http://dx.doi.org/10.1186/s4056001500809. PMID: 25866644
Davankov V., Pavlova L., Tsyurupa M., Brady J., Balsamo M., Yousha E. Polymeric adsorbent for removing toxic proteins from blood of patients with kidney failure. J. Chromatogr. B. Biomed. Sci. Appl. 2000; 739 (1): 73–80. http://dx.doi.org/10.1016/s03784347(99)00554x. PMID: 10744315
 
Rights Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication, with the work 6 month after publication simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Авторы, публикующие статьи в данном журнале, соглашаются на следующее:Авторы сохраняют за собой автороские права и предоставляют журналу право первой публикации работы, которая по истечении 6 месяцев после публикации автоматически лицензируется на условиях Creative Commons Attribution License , которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access).